About BRAF Mutations
Testing for BRAF Mutations in Solid Tumors Can Inform Critical Treatment Decisions
BRAF V600 has been identified as a driver mutation across various solid tumors1
BRAF mutations occur in about 8% of solid tumors, most commonly in melanoma and thyroid cancers2
Frequency of BRAF V600 mutations in common cancers:
Tumor types in this chart do not reflect all that were included in studies of TAFINLAR and MEKINIST. Please see Section 14.6 of the Prescribing Information for both TAFINLAR and MEKINIST for more information about tumor types included in studies of BRAF V600E–mutant solid tumors.
V600E is the most common BRAF mutation in cancer, accounting for up to 90% of BRAF-mutant cancers1
References: 1. Turski ML, Vidwans SJ, Janku F, et al. Genomically driven tumors and actionability across histologies: BRAF-mutant cancers as a paradigm. Mol Cancer Ther. 2016;15(4):533-547. 2. Pratilas CA, Xing F, Solit DB. Targeting oncogenic BRAF in human cancer. Curr Top Microbiol Immunol. 2012;355:83-98. 3. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33(4):406-415. 4. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493-501. 5. He M, Breese V, Hang S, Zhang C, Xiong J, Jackson C. BRAF V600E mutations in endometrial adenocarcinoma. Diagn Mol Pathol. 2013;22(1):35-40. 6. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397-405.